Avantor, Inc. (NYSE:AVTR) Shares Sold by Kintegral Advisory LLC

Kintegral Advisory LLC decreased its position in Avantor, Inc. (NYSE:AVTR) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,878 shares of the company’s stock after selling 1,066 shares during the quarter. Kintegral Advisory LLC’s holdings in Avantor were worth $482,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Creative Planning boosted its stake in shares of Avantor by 54.0% during the 3rd quarter. Creative Planning now owns 28,136 shares of the company’s stock valued at $728,000 after buying an additional 9,866 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new position in shares of Avantor during the 3rd quarter valued at approximately $255,000. Louisiana State Employees Retirement System purchased a new position in shares of Avantor during the 3rd quarter valued at approximately $4,874,000. Forsta AP Fonden boosted its stake in shares of Avantor by 7.0% during the 3rd quarter. Forsta AP Fonden now owns 146,900 shares of the company’s stock valued at $3,800,000 after buying an additional 9,600 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in Avantor by 4.1% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 28,012 shares of the company’s stock worth $725,000 after purchasing an additional 1,091 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Stock Performance

AVTR opened at $17.31 on Monday. The stock has a market cap of $11.78 billion, a PE ratio of 16.64, a P/E/G ratio of 1.57 and a beta of 1.28. The company has a current ratio of 1.07, a quick ratio of 0.70 and a debt-to-equity ratio of 0.54. Avantor, Inc. has a 1 year low of $17.14 and a 1 year high of $28.00. The stock’s 50 day simple moving average is $20.96 and its 200-day simple moving average is $22.93.

Avantor (NYSE:AVTR) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same quarter in the previous year, the firm earned $0.22 EPS. Sell-side analysts forecast that Avantor, Inc. will post 1.06 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on AVTR shares. UBS Group reiterated a “neutral” rating and issued a $25.00 target price (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Barclays lowered their target price on Avantor from $26.00 to $23.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Royal Bank of Canada dropped their price target on Avantor from $33.00 to $31.00 and set an “outperform” rating on the stock in a research note on Monday, February 10th. Wells Fargo & Company decreased their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Finally, Morgan Stanley reduced their price target on Avantor from $27.00 to $25.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Avantor currently has a consensus rating of “Moderate Buy” and an average price target of $25.92.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.